News & Updates

Show Multimedia Only

Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients

12 Apr 2024 by

Patients with gynaecologic cancer who used apixaban for postoperative venous thromboembolism (VTE) prophylaxis achieve similar 90-day and lower 30-day rates of VTE when compared with those who used enoxaparin, reports a study presented at SGO 2024.

Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients

12 Apr 2024

Maintenance fuzuloparib prolongs survival in ovarian cancer

12 Apr 2024 by

Maintenance therapy with fuzuloparib results in significant improvements in progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, who showed response to first-line platinum-based chemotherapy (PBC), reports a study (FZOCUS-1) presented at SGO 2024.

Maintenance fuzuloparib prolongs survival in ovarian cancer

12 Apr 2024

Does teen pregnancy foretell subsequent risk of premature death?

12 Apr 2024

Teenage pregnancy has been linked to an increased risk of premature mortality in early adulthood in a recent study.

Does teen pregnancy foretell subsequent risk of premature death?

12 Apr 2024

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

12 Apr 2024 by

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the ﬁnal analysis of the NORA trial presented at SGO 2024.

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

12 Apr 2024

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

05 Apr 2024 by

A minimally invasive approach to interval debulking surgery appears to be just as effective as the use of an open technique for epithelial ovarian cancer, with no significant difference in overall survival (OS) when complete tumour resection is achieved, according to a study.

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

05 Apr 2024

Noninvasive device targets precancerous cervical lesions with minimal risk

04 Apr 2024 by

A novel device that integrates hexaminolevulinate (HAL) hydrochloride (HCl) with photodynamic therapy for the treatment of cervical histologic high-grade squamous intraepithelial lesions (HSIL) has shown good results in the global phase III APRICITY study, with lasting efficacy and an acceptable safety profile.

Noninvasive device targets precancerous cervical lesions with minimal risk

04 Apr 2024

Vitamin B12 supplementation improves human milk status in mothers

02 Apr 2024

Maternal supplementation with vitamin B12 provides benefits on both short- and long-term human milk (HM) status, as shown in a study.

Vitamin B12 supplementation improves human milk status in mothers

02 Apr 2024

Prenatal topiramate not associated with autism in offspring

02 Apr 2024 by

Prenatal exposure to topiramate does not increase the risk of autism in offspring, a US nationwide cohort study has shown.

Prenatal topiramate not associated with autism in offspring

02 Apr 2024

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

02 Apr 2024 by

Adding pembrolizumab to standard chemotherapy resulted in a favourable overall survival (OS) benefit in patients with advanced or recurrent endometrial cancer compared with chemotherapy alone, regardless of mismatch repair (MMR) status, according to a key prespecified secondary analysis of the NRG-GY018 trial presented at the SGO 2024.

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

02 Apr 2024

Is it safe to use vedolizumab, ustekinumab during pregnancy?

27 Mar 2024

Pregnant women who are being treated with ustekinumab or vedolizumab appear to experience no greater complications as those receiving antitumour necrosis factor (anti-TNF) agents, immunomodulators, or combination anti-TNF/immunomodulators, according to a study.

Is it safe to use vedolizumab, ustekinumab during pregnancy?

27 Mar 2024

News & Updates

Showing Obstetrics & Gynaecology articles

Showing

Specialty:

Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients

Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients

Maintenance fuzuloparib prolongs survival in ovarian cancer

Maintenance fuzuloparib prolongs survival in ovarian cancer

Does teen pregnancy foretell subsequent risk of premature death?

Does teen pregnancy foretell subsequent risk of premature death?

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

Niraparib maintenance yields favourable OS trend in patients with ovarian cancer

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy

Noninvasive device targets precancerous cervical lesions with minimal risk

Noninvasive device targets precancerous cervical lesions with minimal risk

Vitamin B12 supplementation improves human milk status in mothers

Vitamin B12 supplementation improves human milk status in mothers

Prenatal topiramate not associated with autism in offspring

Prenatal topiramate not associated with autism in offspring

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups

Is it safe to use vedolizumab, ustekinumab during pregnancy?

Is it safe to use vedolizumab, ustekinumab during pregnancy?